The EGFR tyrosine kinase inhibitor and antineoplastic agent for the treatment of lung cancer (NSCLC) Osimertinib (28) (Figure 10) was shown to also inhibit LSD1 (IC50 = 3.98 μM). The gene discussed is KDM1A; the disease is non-small cell lung carcinoma.